Refractory pure red cell aplasia associated with B-CLL: successful treatment with a combination of fludarabine, cyclosporin A and erythropoietin.
Shimoni
A
A
Shvidel
L
L
Klepfish
A
A
Shtalrid
M
M
Sigler
E
E
Berrebi
A
A
D015703:Antigens, CD / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D016572:Cyclosporine / Q000627:therapeutic use*; D004921:Erythropoietin / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D016130:Immunophenotyping; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000150:complications / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012010:Red-Cell Aplasia, Pure / Q000097:blood / Q000150:complications / Q000276:immunology / Q000628:therapy*; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D015703:Antigens, CD; D000970:Antineoplastic Agents; D006454:Hemoglobins; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D004921:Erythropoietin; D016572:Cyclosporine; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone